Ecnoglutide

Ecnoglutide (XW003) is a GLP-1 agonist being developed for the treatment of obesity and type 2 diabetes.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Ecnoglutide (XW003) is a GLP-1 agonist being developed for the treatment of obesity and type 2 diabetes. In preclinical trials, "Ecnoglutide showed a favorable potency, pharmacokinetic, and tolerability profile, as well as a simplified manufacturing process" compared to other GLP-1 agonist lipopeptides.

A phase 3 trial published in 20251 showed 9-13% reduction in bodyweight versus placebo over a 48-week treatment, varying by ecnoglutide dose. In January 2026, ecnoglutide injection is approved for marketing in China.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378399009 under CC BY-SA 4.0; modifications have been made.

References

  1. ↩Wikipedia “Ecnoglutide” revision 1378399009 · retrieved 2026-10-20 publication date (×1) · confidence 0.95 revision URL